TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05981001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be administered at 100 mg/m\^2 IV on Days 1, 8 and 15 of each 28-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at 1000 mg/m\^2 IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at area under the concentration-time curve 2 (AUC 2) IV on Days 1 and 8 of each 21-day cycle until unacceptable toxic effects or disease progression or other termination criteria appeared.
Study: NCT05825534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT monitoring
Description: EIT monitoring (PulmoVista 500, Dräger, Lübeck, Germany) will be applied using a dedicated silicon belt with 16 electrodes placed at the level of the fifth intercostal space. The EIT system will be connected to the ventilator and data of gas flow, volume, airway pressure, and impedance will be synchronously collected at 40 Hz. The investigators will perform one simple pressure-volume (PV) curve with a low-flow insufflation of 5 L/min starting from 0 cmH2O. During the low-flow insufflation, both ventilator and EIT-derived PV curves will be recorded. All PV curves will be analysed offline to detect complete and regional airway closures, and measure AOPs.
Study: NCT06439433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid (500-mg bottle)
Description: once a week for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolaevulinic acid (750-mg bottle)
Description: once a week for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once a week for 6 weeks
Study: NCT05504265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preemptive flurbiprofen axetil
Description: 50mg once，30min before induction anesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Postoperative flurbiprofen axetil
Description: 50mg bid
Study: NCT05564689

Intervention type: PROCEDURE
Intervention: Intracoronary flow and pressure
Description: Measurement of absolute coronary flow and resistance
Study: NCT05504265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative flurbiprofen axetil
Description: 50mg bid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia pump
Description: Sufentanil 2.5 μg/kg+ondansetron 8mg, prepared to 100ml normal saline; background dose: 2 ml/h, single press analgesic pump injection volume: 0.5 ml, locking time: 15 min.
Study: NCT04718168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore ENFORM Biomaterial (Preperitoneal)
Description: ENFORM Biomaterial bioabsorbable hernia mesh
Study: NCT06214130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate 500 MG
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate 500 MG
Description: oral intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid 500 MG
Description: oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid 500 MG
Description: oral intake
Study: NCT05615272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bio-PRF
Description: Intervention group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alveogyl
Description: Control group
Study: NCT05693779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise training
Description: Participants will complete an Exercise Treadmill Test at baseline. The 12 weeks exercise program that will be assigned to each patient will be based on these results. The exercise will be three 20-minute exercise sessions per week for 6 weeks. This will increase to four 60-minute exercise sessions per week at increased intensity progressively over the course of the exercise program. The exercise program will involve walking/jogging, elliptical training, or biking 3-4 times per week for up to an hour each session. If participants don't have access to a bike or elliptical, they will be asked to exercise by walking/jogging.~Participants will also a phone call or video chat that takes about 15 minutes per week to discuss the exercise program and take 2 short surveys weekly on the MyDataHelps application and filling out a logbook recording exercise sessions. In addition, participants activity will be measured by using a smartwatch during the study.
Study: NCT04718168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore ENFORM Biomaterial (Preperitoneal)
Description: ENFORM Biomaterial bioabsorbable hernia mesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore ENFORM Biomaterial (Intraperitoneal)
Description: ENFORM Biomaterial bioabsorbable hernia mesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore ENFORM Biomaterial (Intraperitoneal)
Description: ENFORM Biomaterial bioabsorbable hernia mesh
Study: NCT06125808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRO350
Description: Active substance phospholipid esters from herring roe oil (PEHeRo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRO350
Description: Active substance phospholipid esters from herring roe oil (PEHeRo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; as a sunflower oil in capsules similar to the interventional drug product HRO350 in terms of appearance, smell and taste.
Study: NCT04669301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAAT-G
Description: Memory and Attention Adaptation Training (MAAT) is a cognitive-behavioral therapy (CBT)-based intervention for CRCD. As a CBT-based intervention, MAAT focuses on an individual's psychological response to injury as compared to the biological events triggering CRCD. MAAT is a series of manualized workshops delivered by a psychologist via video-conferencing, supplemented by a participant workbook, which provide instruction and practice with adaptive behavioral coping skills, stress management techniques, and compensation strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy (time and attention control)
Description: Supportive Therapy (ST) is a behavioral placebo and controls for non-specific psychotherapeutic factors of the clinician-subject relationship, such as empathy and support, but does not provide active cognitive training. ST utilizes reflective listening to help deepen awareness of participants' emotional experience. Timing and duration of ST sessions will mirror the intervention, and will consist of 10 weekly sessions, 30 to 45 minutes each, delivered by trained psychologists via video-conferencing.
Study: NCT04185402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: In study communities randomized to the Azithromycin Continuation arm, all individuals aged 1 month and older will receive a single mass distribution of azithromycin several weeks after the baseline and 36-month monitoring visits. In study communities randomized to Azithromycin Discontinuation, participants will receive no treatment.
Study: NCT05538572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT3645
Description: PRT3645 capsules will be self-administered once daily, continuously, at the dose-level assigned
Study: NCT06105736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention in a small group platform
Description: RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention in a small group platform
Description: RT is small-group-based, intensive behavioral intervention session delivered twice weekly over a secure remote platform for 60-minutes over 5 weeks. Each session is led by a psychologist trained and certified in RT. Caregiver groups meet at the same frequency and duration but at different times. Each session has a specific focus for teaching participants to identify emotions and incorporation of cognitive behavioral therapy (CBT) and mindfulness skills that are reinforced through repeated practice. Each session will include a review, relaxation, new material didactic, activities to reinforce material, mindfulness, and homework.
Study: NCT04939181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Neuromodulation
Description: The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7. Characteristics of microcurrents:~pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Non-invasive Neuromodulation
Description: The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents.
Study: NCT04901442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aetrex L700 Speed orthotic
Description: An orthotic insole to be inserted into running shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain, and Metatarsalgia. Helps prevent injury, alleviate discomfort and helps reduce fatigue while running
Study: NCT06479265

Intervention type: OTHER
Intervention: Phyical/Cognitve Exercise
Description: Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.

Intervention type: OTHER
Intervention: Phyical/Cognitve Exercise
Description: Participants will report to the CERC and review informed consent with a study investigator. Eligibility assessments (PAR-Q, WCST64, Medical History) will be done post-consent. Data collected will include age, body composition, gender, aerobic capacity, chronic medication use, and treated pathologies. All measurements will occur during one visit. Participants will lay supine for 5 minutes to measure resting heart rate (HR) using an HR monitor. This resting HR, with age-predicted HR max, will determine HR reserve (HRR). Participants will master the WCST64 and identify walking pace on the Blue Goji treadmill. They will complete a baseline 10 Meter Walk Test, followed by the digital WCST64 under 7 conditions, ending with a post-intervention 10 Meter Walk Test.
Study: NCT06327555

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the traditional rehabilitation group
Description: The traditional rehabilitation group takes a face-to-face approach, with therapists providing outpatient rehabilitation instruction twice a week for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the remote rehabilitation group
Description: The telerehabilitation group uses smart wearables and mobile apps worn around the knee joint to perform remote rehabilitation at home. At least twice a week, both sets of training sessions are identical.
Study: NCT05635357

Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole claim is used as the exposure group.

Intervention type: DRUG
Intervention: Exemestane/Letrozole
Description: Exemestane/Letrozole claim is used as the reference group.
Study: NCT06174688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections
Study: NCT05969249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb in vibration training
Description: The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper limb in vibration training
Description: The stroke subjects were all involved in the training,wear upper and lower extremity vibrators,the posture for intervention is hemiplegic upper limbs with shoulder joints slightly bent and abducted at 45 degrees, with elbows bent at 90 degrees and wrists centered. The elbow angle of this posture is set by the elbow joint rotation axis of the upper limb vibrator.~The set angle is the movable angle range of 80-110 degrees of elbow bending. The vibration rehabilitation password accepted by all subjects is Try to keep the elbow joint bent at 90 degrees during the vibration process, Resist the force of the vibration and try not to move.
Study: NCT05418114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: . One group (Group A) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine + 1 ml (500 mg) of 50% Magnesium sulphate. Other group (Group B) will be given local infiltration with 9 ml (180 mg) of 2% lignocaine.
Study: NCT05801588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T'ai Chi and Qigong Rehabilitation
Description: T'ai chi/Qigong is a multidimensional (mind, body, and spirit integrative) and multimodal (strength, flexibility, balance, posture, and light to moderate aerobic) form of exercise that is safe for persons of all ages and physical abilities. The 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation program proposed to be studied is adapted from the WaQi program, a curriculum developed by Master Yang Yang, PhD. The practice is gentle yet powerful, aiming to relieve and prevent back, neck, and hip pain. It has an online teaching module and is uniquely suited for our study population. The program requires no difficult movement transitions, but still contains all essential parts including meditation. The WaQi program has less psychological stress and physical challenge than other exercise activities because it can be performed either sitting, standing, and lying down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The control arm will receive the same 12-week, twice-per-week t'ai chi and qigong gentle movement and meditation, online live T'ai Chi and Qigong teaching module from Jan. 26, 2023 to April 17, 2023.
Study: NCT06174688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injections
Study: NCT06443177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vectris trial leads and stimulation
Description: The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No electrode is placed.
Study: NCT04740281

Intervention type: BEHAVIORAL
Intervention: Footwear
Description: Assessment of footwear
Study: NCT05120973

Intervention type: PROCEDURE
Intervention: multispectral imaging
Description: Sentinel node biopsy with Indocyanine Green -Technetium - Nanocolloid + fluorescein

Intervention type: PROCEDURE
Intervention: fluorescence for lymphatic mapping
Description: Indocyanine green injected in abdominal wall
Study: NCT06241638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B12 0.5 MG/ACTUAT
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Study: NCT06521515

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound Morphology Patterns
Description: Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound Morphology Patterns
Description: Two blinded investigators conducted daily lung ultrasound examinations. Each lung was scanned in six regions, categorizing ultrasound findings into four aeration patterns: normal (N-score 0), moderate (B1-lines score 1), severe (B2-lines score 2), and consolidation (C-score 3). The global LUS score ranged from 0 to 36. Patients were grouped into TLP if they exhibited a tissue-like pattern in any region or DBP if they displayed diffuse B-lines and shred signs in most regions. Localized TLPs indicated concentrated areas of non-aeration.
Study: NCT05887544

Intervention type: OTHER
Intervention: Exposure: Plant-based diet pattern
Description: From dietary records average intake across food groups will be calculated and a plant-based diet index score will be generated to group participants.

Intervention type: OTHER
Intervention: Intervention: Fermented dairy products
Description: 1000g of the product to be consumed 1-2 days prior to spot urine sample.

Intervention type: OTHER
Intervention: Exposure: individual foods and food groups
Description: From the dietary records, average intake of specific foods or food groups will be calcualted.
Study: NCT06445764

Intervention type: OTHER
Group type: OTHER
Intervention: e-learning
Description: Participants will complete an e-learning course over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This course prepares participants for an in-person assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual reality training
Description: Participants will complete a virtual reality training over a two-week period that focuses on skills and knowledge related to the management of in-hospital cardiac arrest. This training prepares participants for an in-person assessment.
Study: NCT05763186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling and rinsing
Description: Comparison of the results of the biological examinations obtained on the 6 tubes collected on the PiccLine with the results of the biological examinations obtained on the peripheral sample.
Study: NCT05853198

Intervention type: OTHER
Group type: OTHER
Intervention: ctDNA analysis
Description: ctDNA amount and mutations analysis
Study: NCT05015127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 680 mg qw by q2w from week 13
Description: HBM9161 680 mg qw by q2w from week 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9161 680 mg qw by q2w from week 7
Description: HBM9161 680 mg qw by q2w from week 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo qw by HBM9161 680mg qw from week 12